Ultrasound, Peds Body Composition, and Neurodevelopmental Outcomes

Sponsor
University of Minnesota (Other)
Overall Status
Recruiting
CT.gov ID
NCT03479515
Collaborator
(none)
80
1
101.4
0.8

Study Details

Study Description

Brief Summary

The overall objective of the proposal is to evaluate the ability of ultrasound to predict the body composition of toddlers in the outpatient clinical setting and to evaluate the relationship between body composition and neurodevelopment.

Condition or Disease Intervention/Treatment Phase
  • Device: Ultrasound

Detailed Description

The investigators will address the hypothesis in the following Specific Aims:

Specific Aim 1: Validate ultrasound as a method to measure whole body fat mass and fat-free mass in toddlers. Body composition will be assessed using ultrasound measurements and the validated method of air displacement plethysmography (ADP).

Specific Aim 2: Determine the effect of a handheld Force-Measuring Ultrasound Probe on intra- and inter-observer variability in ultrasound measurements. A device which measures the force applied to the ultrasound probe will be used to obtain measurements of muscle and adipose tissue thickness (biceps, abdomen, and quadriceps) in toddlers.

Study Design

Study Type:
Observational
Anticipated Enrollment :
80 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Use of Bedside Ultrasound to Monitor Body Composition and Neurodevelopmental Outcomes in Formerly-Premature Toddlers
Actual Study Start Date :
Jul 20, 2018
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Jan 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Formerly-Premature Toddlers

Data will be used to create and evaluate predictive equation

Device: Ultrasound
Ultrasound, ADP, bioimpedance measurements

Outcome Measures

Primary Outcome Measures

  1. Ultrasound Measurements [through study completion, up to 2 years]

    Tissue thickness (adipose and muscle) will be measured in cm using the ultrasound probe.

Secondary Outcome Measures

  1. Body Composition Measurements [through study completion, up to 2 years]

    Fat and fat-free mass will be measured in kilograms using bioimpedance and air displacement plethysmography.

  2. Neurodevelopmental Status for 2 year olds [through study completion, up to 2 years]

    Bayley Scales of Neurodevelopment III will be used to measure neurodevelopmental status at 2 years of age, including cognition, language, and motor scores (composite scoring for each area: Cognitive, 55-145; Language, 47-153; Motor, 46-154).

  3. Neurodevelopmental Status for 3 and 4 year olds [through study completion, up to 2 years]

    Weschler Preschool and Primary Scale of Intelligence (WPPSI) at 3 and 4 years of age will be used to measure neurodevelopmental status for toddlers 3, 4, or 5 years of age. Quotient and Composite scores have a mean of 100 and a standard deviation of 15. Subtest scaled scores have a mean of 10 and a standard deviation of 3.

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 4 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • toddlers who were ≤ 36 weeks gestational age (GA) at birth who attend the University of Minnesota Masonic Children's Hospital NICU Follow Up Clinic

  • written consent obtained from a parent before or at time of visit

Exclusion Criteria:
  • toddlers who require medical support that prevents them from having ADP measurements taken

  • those with an inability to sit in a supported seat for 5 minutes

  • those weighing less than 10 kg

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Minnesota Masonic Children's Hospital Minneapolis Minnesota United States 55455

Sponsors and Collaborators

  • University of Minnesota

Investigators

  • Principal Investigator: Sara Ramel, MD, University of Minnesota

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Minnesota
ClinicalTrials.gov Identifier:
NCT03479515
Other Study ID Numbers:
  • PEDS-2018-25847
First Posted:
Mar 27, 2018
Last Update Posted:
Sep 29, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 29, 2021